Synopsis:
Motilal Oswal MF increased its stake in the HealthCare company by acquiring 1.54 lakh shares via market deals, taking total holding to 5.04% from 4.93%, thereby triggering Regulation 29(1) disclosure as stake crossed the 5% mark.
This company is engaged in setting up and managing hospitals and medical diagnostic services, including scientific testing and consultancy services in the pharmaceutical and medical sector is now in focus after Motilal Oswal MF has acquired some new shares in it.
With market capitalization of Rs. 10,591 cr, the shares of HealthCare Global Enterprises Ltd are currently trading at Rs. 751 per share, from its previous close of Rs. 752.40 per share. The stock has delivered 14% returns in the past month.
News
Motilal Oswal Mutual Fund has acquired additional 1.54 lakh equity shares of HealthCare Global Enterprises Ltd on October 29, 2025 via market transactions, taking its total shareholding in the company to 71.06 lakh equity shares.
Post this incremental acquisition, its stake has crossed the 5% mark, rising from 4.93% earlier to 5.04%, which is 0.11% in increase. The disclosure has been filed under Regulation 29(1) of SEBI SAST Regulations, as shareholding movement beyond 5% requires mandatory reporting.
These 11 Motilal Oswal Mutual Fund schemes, which are Balanced Advantage Fund, S&P BSE Healthcare ETF, Nifty Microcap 250 Index Fund, Multi Cap Fund, Business Cycle Fund, Infrastructure Fund, Active Momentum Fund, Special Opportunities Fund, BSE 1000 Index Fund, Services Fund and Consumption Fun,d together have participated in the recent buying activity in HealthCare Global Enterprises Ltd.
About the company
HealthCare Global Enterprises Ltd (HCG) is one of India’s largest specialized cancer care hospital chains, focused on oncology treatment, diagnostics and precision based therapies. The company operates advanced cancer treatment centres across multiple cities in India and is known for high-end radiation therapy, medical oncology, surgical oncology and day care driven cancer treatment specialization.
The company has shown consistent long-term improvement with profit growing at a strong 19.3% CAGR over the last 5 years. Promoters have also increased their holding by 1.32% last quarter they now hold 63.78 percent, indicating confidence in the business. However, return ratios remain moderate with ROCE at 8.56% and ROE at 5.14%.
FII’s have increased their stake from 2.16% in Q1FY26 to 3.59% in Q2FY26. DII’s have also raised their stake to 18.36% from 13.22% over the same period. The public have reduced their stake from 22.17% to 14.28%.
Sales of the company increased from Rs. 585.16 cr in Q4FY25 to Rs. 613.16 cr in Q1FY26. Operating Profit slightly increased to Rs. 107.79 cr from Rs. 105.63 cr. Net profit slightly declined from Rs. 6.77 cr to Rs. 5.98 cr over the same period.
Written by Manideep Appana
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
